Bevacizumab (Avastin) in ocular processes other than choroidal neovascularization

Ocular Immunology and Inflammation

Volumn 17, Issue 2, 2009, Pages 109-117

  Barkmeier, Andrew J ^a   Akduman, Levent ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Growth factor; Macular edema; Neovascularization; Vascular endothelial

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TRIAMCINOLONE;

BLOOD PRESSURE; BRAIN HEMORRHAGE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; COMORBIDITY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EYE INFLAMMATION; EYE IRRITATION; GLAUCOMA DRAINAGE IMPLANT; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; NEOVASCULAR GLAUCOMA; NONHUMAN; PREMATURITY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINOPATHY; RETROLENTAL FIBROPLASIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; TRANSIENT ISCHEMIC ATTACK; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EYE DISEASES; FILTERING SURGERY; GLAUCOMA; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; POSTOPERATIVE COMPLICATIONS; RETINAL VEIN OCCLUSION; VITREOUS BODY;

EID: 67749122395     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940802596534     Document Type: Review

References (43)

1. Avastin Drug Warning. 2005. Available at: http://www.fda. gov/medwatch/SAFETY/2005/Avastin-dearhcp.pdf
2. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
3. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41:614-625. Review.
4. Fung AE, Rosenfeld PJ, Reichel E. The international intrav-itreal bevacizumab safety study: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
5. Philipp W, Speicher L, Humpel C. Expression of vascular en-dothelial growth factor and its receptors in inflamed and vascu-larized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
6. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
7. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
8. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
9. Tripathi RC, Li J, Tripathi BJ, et al. Increased levels of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232-237.
10. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158.
11. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
12. Jonas JB, Spandau UH, Schlictenbrede F. Intravitreal beva-cizumab for filtering surgery. Ophthalmic Res 2007;39(2):121-22.
13. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37:148-150.
14. Lashkari K, Hirose T, Yazdani J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000;156:1337-1344.
15. Lalwani GA, Buch M, Cardone S, et al. Bevacizumab for salvage treatment in threshold retinopathy of prematurity. Retinal Physician. 2007; Jan/Feb: 77-78.
16. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal beva-cizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233-237.
17. Aiello LP, Avery RL, Arrigg PG, et. Al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopa-thy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
18. The Diabetic Retinopathy Study Research Group. Photocoag-ulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS), DRS Report Number 8. Ophthalmology. 1981;88:583-600.
19. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by virtre-ous hemorrhage. Retina. 2006;26:275-278.
20. Chen E, Park C. Use of intravitreal bevacizumab as a preoper-ative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699-670.
21. Avery RL, Pearlman J, Pieramici DL, et al. Intravitreal beva-cizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
22. Tonello M, Costa RA, Almeida FPP, et al. Panretinal photocoag-ulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol Scand. 2007 Nov (epub ahead of print).
23. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Group Report Number 1. Arch Ophthalmol. 1985;103:1796-1806.
24. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triam-cinolone versus bevacizumab for refractory diabetic mac-ular oedema (IBEME study). Br J Ophthalmol. 2008;92:76-80.
25. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Beva-cizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-126.
26. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114;1860-1867.
27. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794-796.
28. Coma MC, Sobrin L, Onal S, et al. Intravitreal beva-cizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574-1579.
29. Mackensen F, Heinz C, Becker M, et al. Intravitreal beva-cizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41-45.
30. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovasculariza-tion and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol. 2002;120:1644-1650.
31. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal be-vacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004-1012.
32. Ferrara DC, Koizumi H, Spaide RF, et al. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. 2007;144:864-871.
33. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina. 2007;27:1013-1019.
34. NomaH,FunatsuH,YamasakiM,etal.Pathogenesisofmacular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
35. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419-425.
36. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatmentof macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351-355.
37. Finger PT, Chin K. Anti-vascular endothelial growth factor be-vacizumab (avastin) for radiation retinopathy. Arch Ophthalmol. 2007;125:751-756.
38. Mason JO III, Albert MA Jr, Persaud, TO, et al. Intravitreal be-vacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina. 2007;27:903-907.
39. Arevalo JF, Garcia-Amaris RA, Roca JA, et al. Primary intravit-real bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg. 2007;33:2098-2105.
40. Spitzer MS, Ziemssen F, Yoeruek E, et al. Efficacy of in-travitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg. 2008;34:70-75.
41. Issa PC, Holz FG, Scholl HPN, et al. Findings in fluorescein angiography and optical coherence tomography after intravit-real bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology. 2007;114:1736-1742.
42. Amselem L, Montero J, Diaz-Llopis M, et al. Intravitreal beva-cizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol. 2007;144:122-124.
43. Melo GB, Farah ME, Aggio FB. Intravitreal injection of beva-cizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand. 2007;85:461-463.